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OBJECTIVE: To characterize the findings of behavioral hearing assessment in HIV-positive individuals who
received and did not receive antiretroviral treatment.
METHODS: This research was a cross-sectional study. The participants were 45 HIV-positive individuals (18 not
exposed and 27 exposed to antiretroviral treatment) and 30 control-group individuals. All subjects completed
an audiological evaluation through pure-tone audiometry, speech audiometry, and high-frequency
audiometry.
RESULTS: The hearing thresholds obtained by pure-tone audiometry were different between groups. The
group that had received antiretroviral treatment had higher thresholds for the frequencies ranging from 250 to
3000 Hz compared with the control group and the group not exposed to treatment. In the range of frequencies
from 4000 through 8000 Hz, the HIV-positive groups presented with higher thresholds than did the control
group. The hearing thresholds determined by high-frequency audiometry were different between groups, with
higher thresholds in the HIV-positive groups.
CONCLUSION: HIV-positive individuals presented poorer results in pure-tone and high-frequency audiometry,
suggesting impairment of the peripheral auditory pathway. Individuals who received antiretroviral treatment
presented poorer results on both tests compared with individuals not exposed to antiretroviral treatment.
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& INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is caused
by human immunodeficiency virus (HIV), the etiological
agent that causes significant immunological impairment in
individuals with AIDS. This retrovirus mainly invades cells
related to the immune system, triggering a progressive
reduction of lymphocyte and hence causing opportunistic
infections. HIV is transmitted by sexual intercourse, blood
transfusion, the use of injection drugs, occupational acci-
dents and perinatal transmission (1). In Brazil, HIV
prevalence is approximately 0.6% in the population between
15 and 49 years of age, 0.4% among women and 0.8% among
men (2).
Nearly 75% of adults with AIDS present some types of
hearing impairment due to opportunistic infections or
treatments with ototoxic medications (3). The incidence of
hearing impairment among patients with HIV/AIDS varies
from 20% to 40% (4-7) and the hearing loss may be due to
outer, middle and/or inner ear pathologies.
Infections of the upper airways, and especially sinusitis,
external otitis, and otitis media, are among the infections that
might affect individuals with AIDS (8). It is known that otitis
media may cause temporary peripheral hearing loss and
must be diagnosed as early as possible so that adequate
medical treatment is established. These individuals may also
present cochlear pathology/inner ear impairments due to the
direct action of the virus (5,6,9,10) and the use of antire-
troviral drugs and/or potentially ototoxic medications (11),
which can cause sensorineural hearing loss.
This is the first study in a series of two that intended to
examine the audiological manifestations of HIV’s action on
the auditory system, from its most peripheral to its most
central portion, in seropositive individuals. The aim of this
first study was to characterize the audiological profile of
HIV-positive individuals and to compare the results
obtained between HIV-positive individuals who received
and did not receive antiretroviral treatment (ART).
& MATERIALS AND METHODS
The present research consisted of a prospective cross-
sectional study that was approved by the Ethics Committee
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for the Analysis of Research Projects (CAPPesq) of the
Clinical Board of the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo (HCFMUSP), under
protocol number 1026/04.
All participants signed the Free and Informed Consent
Term, according to Resolution 196/96. The procedures were
conducted at the Investigation Laboratory in Auditory Evoked
Potentials of the Department of Physical Therapy, Speech-
Language Pathology and Audiology and Occupational Therapy
of the Faculdade de Medicina da Universidade de Sa˜o Paulo
(FMUSP).
The participants were 75 individuals aged from 20 to 60
who were divided into three groups (see the descriptions of
the groups in Table 1):
Research Group I (RGI): composed by 18 HIV-positive
subjects (confirmed by serology) not exposed to ART.
Research Group II (RGII): composed by 27 HIV-positive
subjects (confirmed by serology) exposed to ART with at
least three of the following drugs (combination therapy or
highly active antiretroviral therapy): lamivudine, zidovu-
dine, efavirenz, didanosine, nevirapine, lopinavir-r, tenofo-
vir, stavudine, indinavir, abacavir, amprenavir, ritonavir,
and atazanavir.
Control Group (CG): composed by 30 non-HIV-infected
subjects (confirmed by serology) with no medical history of
psychiatric or neurological conditions and no audiological
or auditory processing complaints.
For all three groups, the following exclusion criteria were
considered: pregnancy, ongoing opportunistic infections,
the presence of any other clinical and/or cognitive impair-
ment that could prevent the adequate conduction of
audiological exams and a history of otologic surgery and/
or otologic diseases not related to HIV.
RGI and RGII were referred by Casa da AIDS – Fundac¸a˜o
Zerbini and by the Health Services of the Municipal
Network Specializing in Sexually Transmitted Diseases
(STD/AIDS) of the Sa˜o Paulo Department of Health.
Data regarding eligibility criteria of the sample, as well as
the presence of risk indicators for hearing impairments
reported in the case history were retrieved from subjects’
records. Auditory complaints were obtained through a
closed-ended questionnaire. Subsequently, a visual inspec-
tion of the external ear canal was performed using a Heine
otoscope.
Acoustic immittance measures (tympanometry and ipsi-
lateral and contralateral acoustic reflex measures for
frequencies of 500, 1000, 2000 and 4000 Hz) were performed
for the electroacoustic assessment of hearing using the
middle ear analyzer model GSI-33 from Grason Stadler
(ANSI S3.39-1987). Each subject was instructed to remain
quiet, to refrain from talking, and to minimize head
movement. The results were classified as normal or altered
according to the normality criteria described: a type A
tympanometric curve; ipsilateral acoustic reflexes present at
frequencies of 500, 1000 and 2000 Hz between 80 and 95 dB
HL; and contralateral acoustic reflexes present at frequen-
cies of 500, 1000 and 2000 Hz between 90 and 105 dB HL
(12,13).
The behavioral hearing assessment (conventional pure-
tone audiometry (PTA) and high-frequency audiometry
(HFA)) was conducted using the audiometer model GSI-61
from Grason Stadler. Model TDH-50 supra-aural head-
phone (Telephonics) was used for conventional PTA, and
for HFA, model HDA-200 (Sennheiser) (standards ANSI
S3.6-1989 and IEC-1988) was used. The subject had to
remain seated in a soundproof booth (ANSI S3.1-1991
standard of environmental quantity of noise).
All individuals were initially tested by PTA at frequencies
of 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz, and,
when necessary, bone-conduction testing was performed at
frequencies of 500, 1000, 2000, 3000 and 4000 Hz. Speech
audiometry, consisting of speech recognition threshold
(SRT) testing and suprathreshold word-recognition testing
(SWRT), used the lists of words proposed by Santos and
Russo (14).
The PTA results were classified as normal or abnormal,
with the following considered as normal: hearing thresholds
lower than or equal to 20 dB HL for the frequencies tested
(15); SRT responses up to or equal to 10 dB over the hearing
thresholds obtained at frequencies of 500, 1000 and 2000 Hz
during the PTA (14); and SWRT with a percentage of correct
answers between 88% and 100% at an intensity 30 dB above
the SRT (16). Abnormal results in the PTA were classified as
follows: high-frequency sensorineural hearing loss (altered
results over 3000 Hz), conductive hearing loss, mixed
hearing loss, sensorineural hearing loss and conductive
hearing loss or mixed hearing loss plus sensorineural
hearing loss (when each ear presented a different result)
(17).
The HFA was also conducted through air conduction at
frequencies of 9000, 10000, 11200, 12500, 14000, 16000, 18000
and 20000 Hz. According to a study by Burguetti et al. (18)
and considering that HFA is performed in 5-dB HL
intervals, the following cutoff values were established as
normal, based on frequency and age range (Table 2):
Both electroacoustic and behavioral assessments were
performed by the same evaluator (a certified audiologist)
and on the same day to avoid the effects of other variables
on the results.
When abnormal results were obtained, the patient was
referred for otorhinolaryngological assessment and treatment
Table 1 - Descriptive analysis of the Control Group,
Research Group I, and Research Group II regarding
gender, age, hearing complaints, CD4+ T lymphocytes
and the duration of HIV infection.
CG RGI RGII
Number of subjects 30 18 27
R:= 14516 4514 9518
Age* 25.6¡6.1 39.4¡8.1 40.3¡6.7
Hearing complaints (%) - 61 89
CD4+** - 585.3¡242.0 477.0¡273.3
Duration of infection*** 86.5¡57.7 111.6¡57.5
R: female; =: male.
*In years (mean ¡ standard deviation).
**Cells per mm3.
***In months.
Table 2 - Normality cutoff values in high-frequency
audiometry (in dB HL) by frequency and age range.
9 kHz 10 kHz 12.5 Hz 14 kHz 16 kHz 18 kHz 20 kHz
20-29 years 15 15 15 15 30 30 10
30-39 years 30 30 35 45 55 35 15
.40 years 30 35 55 90 60 40 20
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and instructed to return in three months for audiological
monitoring.
Statistical methods
The electroacoustic and behavioral results were qualita-
tively and quantitatively analyzed for all three groups.
In the analysis of qualitative data (categorical), the results
were described as proportions of alterations and as types of
alterations according to the assessment criteria. For this
purpose, the Chi-squared test (X2) (without Yates correc-
tion) was used, following the Cochran restrictions; when
these restrictions were present, Fisher’s exact test was
performed.
For the analysis of quantitative (continuous) data, the
mean, median, standard deviation, minimum and max-
imum values were obtained for the results of each
assessment in each group. Additionally, the mean values
obtained for RGI, RGII and the CG were compared, and the
significance level was verified for each comparison. This
analysis applied the Mann-Whitney U test in the case of two
independent samples or the Kruskal-Wallis test in the case
of three or more independent samples and the Wilcoxon
signed rank test (Z). Differences between means were tested
using one-way analysis of variance (ANOVA) (F) in the case
of three or more samples.
The Spearman correlation coefficient (r) was used to
evaluate the relationship between continuous variables and
the biserial correlation coefficient (rb) was used to evaluate
the relationship between categorical and continuous vari-
ables. Lacking data were excluded from the analysis.
Probability values (p) lower than 0.05 were considered
statistically significant, except when a potential problem
involving multiple comparisons was identified. In this case,
the Bonferroni correction (calculated by dividing 0.05 by the
number of multiple comparisons performed) was used. This
situation occurred in the following analyses: the comparison
between right and left ear scores and the comparison of the
hearing assessment parameters between groups (corrected
p-value of 0.001).
In the qualitative analyses, when the proportions of
alterations in behavioral and electroacoustic assessments
were compared, the corrected p-value was 0.005 because
nine analyses were performed. When two-by-two analyses
were conducted, the corrected p-value was 0.017 (three
analyses).
All analyses used Statistical Package for the Social
Sciences (SPSS) 15 for Windows.
& RESULTS
Data regarding the auditory complaints reported in the
questionnaire revealed no significant differences between
RGI and RGII (p= 0.064): 61% of RGI and 89% of RGII
presented hearing complaints. The most frequent symptom
found among HIV-positive subjects in RGI was dizziness
(61% of the cases), followed by tinnitus (39%) and a
sensation of ear fullness (33%). In RGII, hearing loss was
most frequent (52% of the cases), followed by tinnitus (44%)
and dizziness (33%).
The comparison between the right and left ears for each
group (Wilcoxon signed rank test) did not show significant
differences for any frequencies in the PTA and also for the
SRT and SWRT. Hence, the three groups were compared
based on the mean values for the right and left ears of each
subject (Figure 1).
The results obtained in the PTA, SRT and SWRT were
significantly different between the CG, RGI and RGII
(Kruskal-Wallis test, p,0.001). To identify where these
differences occurred, the Mann-Whitney test was used to
compare the groups in pairs and the Bonferroni correction
was used in sequence for multiple comparisons (a sig-
nificance level of p,0.017 was used in this test).
This group comparison evidenced the following results:
the mean hearing thresholds obtained in the PTA from 250
to 2000 Hz and in the SRT of RGII were significantly higher
than in the other groups (p,0.001). At a frequency of
3000 Hz in the PTA, the mean hearing thresholds in the CG
were significantly lower than in RGI (p,0.004), which were
lower than in RGII (p,0.003). The mean hearing thresholds
obtained in the PTA from 4000 to 8000 Hz were significantly
lower in the CG than in the other groups (p,0.001). The
mean results in the SWRT were higher in RGII than in the
CG (p,0.001).
No significant differences were evident between the
hearing thresholds obtained in the HFA for the right and
left ears for all groups (Wilcoxon signed-rank test). Thus, for
the subsequent analyses, the mean values for both ears were
used.
The comparative analysis of the hearing thresholds
obtained in the HFA (Figure 2) showed significantly
Figure 1 -Mean hearing thresholds for the pure-tone audiometry frequencies in both the right and the left ears for the Control Group,
Research Group I, and Research Group II.
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different values between the CG, RGI and RGII at all
frequencies assessed (Kruskal-Wallis test, p,0.001).
The Mann-Whitney test was used for two-by-two com-
parisons, followed by the Bonferroni correction for multiple
comparisons (with a significance level of p,0.017), to
identify where these differences occurred. These analyses
showed that the mean hearing thresholds obtained in the
CG at all high frequencies (except 10 kHz, for which
p= 0.033) were significantly lower than those obtained in
RGI. The two-by-two comparisons between the CG and
RGII yielded significant results (p,0.001) for all high
frequencies. In contrast, the comparisons between RGI and
RGII did not show significant differences (Table 3).
It is important to emphasize the significant differences
obtained between the proportions of alterations in the HFA
and in the PTA for all three groups in the present study.
Considering the three groups, there was a higher proportion
of alterations in the HFA compared with the PTA. RGI
presented 27.8% of alterations in the PTA and 58.8% in the
HFA, and RGII presented 48.1% of the altered results in the
PTA and 73.9% in the HFA (4).
Regarding the proportions of the types of hearing
alterations in the PTA, 80% of high-frequency sensorineural
hearing loss and 20% of conductive hearing loss occurred in
RGI, whereas RGII presented 38.5% of sensorineural
hearing loss, 30.8% of conductive hearing loss and 15.4%
of high-frequency sensorineural hearing loss (Table 5).
& DISCUSSION
In the present study, individuals in both RGI (not exposed
to ART) and RGII (exposed to ART) presented with auditory
complaints. Many studies in the literature have reported an
association between HIV infection and otoneurological signs
and symptoms, emphasizing that subjects with AIDS
frequently present with auditory complaints due to otorhi-
nolaryngological/otologic manifestations that are common
in any stage of the disease and that cause specific
symptoms, such as hearing loss, tinnitus, dizziness, and
sensations of ear fullness (4-7,19-24).
In a study by Ceccarelli et al. (20), the most frequent
auditory complaints among AIDS patients in the initial or
asymptomatic stage were tinnitus (in 50% of the cases) and
vertigo (35%). Subjects also complained of hearing loss (25%
of the cases), a sensation of ear fullness (15%), non-rotatory
dizziness (10%) and unspecific headache (20%). In the
present study, the most frequent symptom reported by
seropositive individuals not exposed to ART (RGI) was
dizziness (61% of the cases) and in the group exposed to
ART (RGII), hearing loss was most frequent (52% of the
cases). These results are in agreement with the symptoms
reported in the previous study, although with different
proportions.
Figure 2 - Mean hearing thresholds for the high-frequency audiometry frequencies in both the right and left ears for the Control
Group, Research Group I, and Research Group II.
Table 3 - Two-to-two comparisons of the Control Group,
Research Group I, and Research Group II regarding the
hearing thresholds obtained at high frequencies
according to the Mann-Whitney test.
Comparison between groups U Z p
9 kHz
CG X RGI 130.00 -2.79 0.005*
CG X RGII 84.00 -4.71 ,0.001*
RGI X RGII 137.50 -1.59 0.111
10 kHz
CG X RGI 159.50 -2.13 0.033
CG X RGII 74.50 -4.88 ,0.001*
RGI X RGII 131.50 -1.76 0.079
11.2 kHz
CG X RGI 125.50 -2.88 0.004*
CG X RGII 41.00 -5.47 ,0.001*
RGI X RGII 117.00 -2.15 0.032
12.5 kHz
CG X RGI 133.50 -2.70 0.007*
CG X RGII 59.00 -5.14 ,0.001*
RGI X RGII 145.50 -1.37 0.171
14 kHz
CG X RGI 123.50 -2.93 0.003*
CG X RGII 33.00 -5.61 ,0.001*
RGI X RGII 123.00 -1.99 0.047
16 kHz
CG X RGI 111.00 -3.20 0.001*
CG X RGII 19.00 -5.86 ,0.001*
RGI X RGII 116.50 -2.17 0.030
18 kHz
CG X RGI 112.00 -3.18 0.001*
CG X RGII 12.50 -5.99 ,0.001*
RGI X RGII 82.00 -3.13 0.002
20 kHz
CG X RGI 107.00 -3.13 0.002*
CG X RGII 31.00 -5.70 ,0.001*
RGI X RGII 96.00 -2.56 0.010
p,0.017 was considered to indicate statistical significance according to
the Bonferroni correction.
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Another study observed that 8.6% of 162 patients treated
with antiretroviral drugs and 5.8% of 122 untreated patients
reported otoneurological complaints (23). Hearing loss,
accompanied or unaccompanied by tinnitus, represented
78.5% of the complaints in the treated group and 57.1% in
the untreated group. These findings were not corroborated
by the present study, in which both individuals exposed
(RGII) and individuals not exposed (RGI) to ART predomi-
nantly presented hearing complaints (89% and 61%,
respectively).
The results obtained in the PTA at all frequencies tested,
as well as in the SWRT, were different between groups. RGII
presented higher hearing thresholds than CG at all
frequencies and than RGI at frequencies from 250 to
3000 Hz. Significant differences between groups were also
found in the comparison of the proportions of alterations in
the PTA: RGI and RGII had higher proportions of hearing
loss compared with the CG (27.8% and 48.1%, respectively).
These results corroborate the data presented by Salzer (19)
and Carvalho et al. (25), who referred to hearing loss as a
common otologic manifestation in HIV-positive individuals,
and the findings of many other authors who verified that
hearing alterations can be present in up to 33% of HIV-
positive patients (4-7,26).
However, the results obtained disagree with those found
in a study with 30 seropositive patients, which reported
normal results for conventional PTA (27).
Many hypotheses can be posited about the causes of the
auditory manifestations observed in the HIV-positive
groups in this study. Regarding RGI, the hearing loss might
have been due to the direct action of the virus on the
auditory system structures (23,28,29). As for RGII, the
possible etiological factors associated with the hearing loss
might have been the direct action of the virus on the
auditory system structures, the presence of opportunistic
infections and/or the use of ototoxic drugs (25,30).
RGII was more susceptible to auditory alterations
compared with RGI. A possible interpretation of these data
is that the use of antiretroviral drugs may have caused a
higher incidence of hearing loss due to its ototoxicity,
especially with the new antiretroviral therapies currently
used (combined therapy or highly active antiretroviral
therapy (HAART)). This aspect has been emphasized in
the literature by many researchers (22,29,30).
In the study with HIV-positive patients, the group
submitted to antiretroviral therapy presented higher
susceptibility to hearing loss than untreated individuals,
which was evidenced by a higher occurrence of hearing
alterations in the individuals exposed to antiretroviral
therapy (29).
It is worth emphasizing that all RGII patients in the
present study used combined therapy (HAART), which has
been reported in the literature as the cause of adverse side
effects, such as ototoxicity (22,31-33). However, this aspect
was not observed in a study that assessed two groups of
patients (exposed or not exposed to antiretroviral drugs)
and did not find a significant correlation between anti-
retroviral therapy and ototoxicity (23).
Another hypothesis is that because RGII was composed of
individuals with a longer duration of HIV infection (mean
of 111.6 months), these subjects may have been exposed to
the direct action of the virus on the auditory system
structures for longer. These aspects have also been
mentioned in specialized literature (30).
The diversity of auditory alterations observed in HIV-
positive patients in the present study was also described by
a previous study, which indicated that these subjects’
hearing loss could be either conductive or sensorineural,
in varied degrees (from mild to profound) and with no
specific configuration (6).
Regarding the types of alterations found in the PTA in the
present study, the most frequently observed alteration in
both HIV-positive groups was sensorineural hearing loss: in
RGI, high-frequency sensorineural hearing loss (80% of
altered cases were at frequencies over 3000 Hz) and in RGII,
sensorineural hearing loss also affecting middle and low
frequencies (38.5% of the altered cases). These findings
corroborate those reported in the literature (5,30,34-36),
which found a predominance of sensorineural hearing loss
in HIV-positive patients, mainly at high frequencies.
Regarding inner ear alterations, sensorineural hearing
loss in individuals with HIV may be due to opportunistic
diseases or ototoxic drugs (32). These authors attributed the
hearing loss associated with antiretroviral therapy to
mitochondrial DNA lesions.
According to several studies, sensorineural hearing loss in
individuals with HIV/AIDS has typically been observed to
undergo a steeper decrease at high frequencies, similar to
the results for RGI in the present study (5,30,34).
Considering this type of audiometric configuration, a
significant difference was found between RGI and RGII
(80% of occurrences in RGI and 15.4% in RGII).
In compiling the international literature, it is estimated
that 20% to 50% of the HIV-positive population presents
different levels of sensorineural hearing loss. Several
authors have noted that sensorineural hearing loss appears
to be less severe in patients with more serious HIV
infections (4,5). This phenomenon explains why, in the
present study, RGI presented sensorineural hearing loss
only at higher frequencies, whereas RGII experienced
sensorineural loss that also affected hearing at middle and
low frequencies.
The second most frequent alteration found in the PTA for
RGI and RGII was conductive hearing loss due to middle-
ear impairments, which was present in 20% of the altered
cases in RGI and in 30.8% in RGII. Hence, as in other studies
(4,19,37), we verified the presence of conductive and/or
sensorineural hearing loss in HIV-infected individuals.
Regarding conductive impairments, both groups (RGI
and RGII) presented conductive or mixed hearing loss,
which was observed in 15.4% of the altered cases in RGII.
Authors have reported the occurrence of otorhinolaryngo-
logical manifestations in patients with HIV (37) and have
verified that 20% of the subjects evaluated presented
otologic complaints. Additionally, chronic otitis media was
the otologic disease most commonly found.
We emphasize that the RGII presented higher proportion
of conductive hearing loss than RGI, which may be due to
the fact that the RGII is composed by individuals infected by
HIV for a longer time and, hence, presenting steeper
immunosuppression, resulting in higher vulnerability to
infections, like otitis media.
Regarding the HFA, the hearing thresholds obtained at all
frequencies tested were significantly different between
groups, and RGI and RGII presented higher thresholds for
the frequencies between 9 kHz and 20 kHz compared to
CG.
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These results corroborate the findings of Juan (35), who
observed significant differences in the hearing thresholds
presented by subjects with HIV/AIDS and healthy indivi-
duals during HFA at all frequencies tested; the thresholds
were higher among the individuals with HIV/AIDS.
In the comparison between groups regarding the propor-
tions of alterations in the HFA, significant differences were
verified (Table 4), with a higher proportion of alterations in
RGI and RGII (58.8% and 73.9%, respectively) than in the
CG (16.7%). A higher incidence of HFA alterations in HIV-
positive individuals was also found in studies reported in
the specialized literature (27,29,35). Whereas Domenech
et al. (27) observed the presence of alterations in the HFA of
23% of the seropositive patients in their sample, Juan (35)
verified that 88% of individuals with HIV/AIDS had HFA
alterations.
However, in the present study, no significant difference
was found between RGI and RGII regarding the proportions
of alterations in the HFA. It was verified that the group
exposed to ART presented with a higher percentage of
altered results (73.9%) than the group not exposed to
treatment did (58.8%). These results corroborate those of
Matas et al. (29), who also found more HFA alterations in a
group exposed to ART compared with a group that was not
exposed.
The great difference obtained between the proportions of
alterations in the HFA and in PTA for all three groups
emphasizes the importance of conducting HFA in HIV-
positive patients, since this assessment was sensitive to
early identify hearing impairments that would not be
detected in conventional PTA. As in the PTA, these high-
frequency hearing impairments might be due to the use of
potentially ototoxic medications, as noted by several
previous studies that researched the ototoxicity of antire-
troviral therapy, especially given the association with
different drugs (22,31,38). Alternatively, the hearing loss at
high frequencies may be caused by the direct action of the
virus on the inner ear structures with the progression of the
disease (4,30,39).
Otorhinolaryngological manifestations are common in
individuals with AIDS (21). Thus, we emphasize the
importance of early diagnosis and of aggressive treatment
for otologic diseases related to HIV, with the aim of
providing significant improvement of the symptoms.
HIV-positive individuals present alterations in behavioral
and electroacoustic assessments of hearing (PTA, HFA, and
acoustic immittance measures), suggesting impairment in
the peripheral auditory pathway. The group exposed to
ART presents higher proportion of alterations than the
group not exposed to this treatment.
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